The present invention provides a method for monitoring esophageal adenocarcinoma (EAC) disease progression in a subject, the method comprising: obtaining a biological sample from the subject; measuring with a quantitative analytical method at least one metabolite; determining a metabolomic biosignature of EAC disease progression based on a comparison of quantitative data for the at least one metabolite to corresponding data obtained for at least one reference sample; and identifying active EAC disease progression in the subject if the quantity of the at least one metabolite in the sample from the subject is greater than that found in the at least one reference sample.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.

Provided are anti-CD47 antibodies and fragments thereof. The antibodies and fragments thereof specifically bind to the CD47 protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and atherosclerosis are also provided.

Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.

Provided are a method for determining whether a subject suffering from a brain tumor is an eligible person for a tailor-made peptide vaccine composition including at least one peptide antigen, a kit used in the aforesaid determination method, and a method for treating a subject suffering from a brain tumor by administering a tailor-made peptide vaccine composition including at least one peptide antigen.

The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering breast cancer and for classifying a subject from breast cancer into a cohort.

The disclosure relates to bispecific antibodies against CD3 and BCMA for use in the treatment of diseases. The disclosure provides methods of determining the responsiveness of a patient to such treatment and relates to diagnostic assays.

The present invention relates to a vasopressin receptor 1B (V.sub.1B) antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in patients showing an elevated arginine vasopressin (AVP) level and/or an elevated copeptin level. The present invention further relates to a method for predicting the treatment response to a V.sub.1B antagonist in patients with depressive symptoms and/or anxiety symptoms.

An in vitro method for diagnosing a brain tumour in a human test subject comprising: determining the concentration of at least two metabolites comprised in a biofluid sample obtained from the human test subject; comparing the concentration of the at least two metabolites in the biofluid sample with the concentration of the same at least two metabolites in at least one reference standard obtained from a non-tumour bearing subject and/or a tumour bearing subject; and identifying a concentration difference for each of the at least two metabolites in the biofluid sample relative to the reference standard; wherein the concentration difference for each of the at least two metabolites in the biofluid sample correlates with the presence of a brain tumour. The invention also relates to a data-storage medium comprising data obtained by a method of the invention.